| 영문 | severe acute respiratory syndrome(SARS) | 한글 | 사스 |
|---|---|---|---|
| 설명 | 중국 광동 지역에서 가장 먼저 발생한 전염성 호흡기 질환으로 세계보건기구(WHO)에서 ‘중증급성호흡증후군(SARS)'으로 명명했다. 섭씨 38도 이상의 고열과 기침, 호흡곤란, 저산소증, X선상의 폐렴증상 중 하나 이상의 증상이 나타나며, 두통, 근육통, 식욕부진, 피로감, 발진, 설사를 동반할 수 있다. 초기 증상은 감기와 비슷하지만 폐렴으로 발전하면 치명적일 수 있다. 현재 밝혀진 감염경로는 환자가 재채기나 기침할 때 내뿜는 침방울이고, 이것이 다른 사람의 호흡기로 들어갈 때 전염된다. 침방울이 전달되는 거리는 보통 1m로 보고 있다. 공기를 통해 전염이 가능하다는 주장이 제기됐지만 아직 확인되지 않았다. 원인균은 변종 코로나바이러스로 밝혀졌다. |
||
| 영문 | severe acute respiratory syndrome(SARS) | 한글 | 중증급성호흡증후군 |
|---|---|---|---|
| 설명 | 중국 광동 지역에서 가장 먼저 발생한 전염성호흡기병으로 세계보건기구(WHO)에서 ‘중증급성호흡증후군(SARS)'으로 명명했다. 섭씨 38도 이상의 고열과 기침, 호흡곤란, 저산소증, X선상의 폐렴증상 중 하나 이상의 증상이 나타나며, 두통, 근육통, 식욕부진, 피로감, 발진, 설사를 동반할 수 있다. 초기 증상은 감기와 비슷하지만 폐렴으로 발전하면 치명적일 수 있다. 현재 밝혀진 감염경로는 환자가 재채기나 기침할 때 내뿜는 침방울이고, 이것이 다른 사람의 호흡기로 들어갈 때 전염된다. 침방울이 전달되는 거리는 보통 1m로 보고 있다. 공기를 통해 전염이 가능하다는 주장이 제기됐지만 아직 확인되지 않았다. 원인균은 변종 코로나바이러스로 밝혀졌다. |
||
| 영문 | respiratory distress syndrome(RDS) | 한글 | 호흡곤란증후군 |
|---|---|---|---|
| 설명 | 폐포와 폐모세혈관 사이에 부종으로 인한 확산능 감소로 호흡곤란과 청색증을 보이는 상태로 감염, 수술, 외상 등 모든 종류의 스트레스상황에서 발생할 수 있다. 치료는 선행 요인의 교정과 적절한 혈액내 산소농도 유지이다. |
||
| ARD | absolute reaction of degeneration; acute radiation disease; acute respiratory disease; adult respira... |
|---|---|
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| RC | an electronic circuit containing a resistor and capacitor in series; radiocarpal; reaction center; r... |
| ESI | elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection |
| ACE inhibitor | angiotensin converting enzyme inhibitor |
|---|---|
| ARDS | Acute respiratory distress syndrome |
| ARF | Acute Respiratory Failure |
| ARI | Acute Respiratory Infection |
| ARI | Acute Respiratory tract Infections |
| respiratory inhibitor | A compound that inhibits the respiratory chain. Synonym: respiratory poison. (05 Mar 2000) |
|---|
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
|---|---|
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |
| mechanism-based inhibitor | A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme. Synonym: mechanism-based inhibitor. (05 Mar 2000) |
| glucosidase inhibitor | Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence. (05 Mar 2000) |
| medication, ace-inhibitor | Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|